The Place of Biological Markers to Predict the Response after Neoadjuvant Treatment in Esophageal CancerMircea Costache1,3, Bogdan Filip1,2*, Dragos Viorel Scripcariu1,2, Nicolae Danila1,3 and Viorel Scripcariu1,2
- *Corresponding Author:
- Filip Bogdan
Department of Surgery, University of Medicine and Pharmacy
Gr. T. Popa, Iași, 1st Surgical Unit
Regional Institute of Oncology, Iași, Romania
Tel: +400745 25 3149
Fax: +400374 2788 02
E-mail: [email protected]
Received date: December 20, 2016; Accepted date: December 26, 2016; Published date: January 02, 2017
Citation: Costache M, Filip B, Scripcariu DV, Danila N, Scripcariu V. The Place of Biological Markers to Predict the Response after Neoadjuvant Treatment in Esophageal Cancer. Journal of Surgery [Jurnalul de chirurgie]. 2017; 13(1): 1-3 DOI: 10.7438/1584- 9341-13-1-1
Copyright: © 2017 Costache M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Esophageal cancer remains one of the most severe malignancies in terms of overall survival despite the introduction of novel radiation regimens and chemotherapy agents. Many of the patients are diagnosed in advanced cases in which a multimodal treatment protocol is applied, finding the biomarkers that are involved in the resistance to neoadjuvant treatment could select the subgroup of patients that could be submitted either to surgical treatment or to an experimental drug trial. Hereby, we reviewed the potential biomarkers (immunohistochemical, blood-based, miRNA markers and gene expression profiling) that promised novel therapeutic pathways protocols.